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Although therapeutic potential of neurotrophic factors (NTFs) has been well recognized for
over two decades, attempts to translate that potential to the clinic have been disap-
pointing, largely due to significant obstacles in delivery, including inadequate protein dose/
kinetics released at target sites. Considerable efforts have been made to improve the
therapeutic performance of NTFs. This articles reviews recent developments in localized
delivery systems of NTFs for the neurological disorders treatments with a main focus on
sustained delivery strategies. Different non-covalent binding approaches have been
employed to immobilize proteins in hydrogels, microspheres, electrospun nanofibers, and
their combined systems, which serve as depots for sustained local release of NTFs. The
challenges associated with current NTFs delivery systems and how these systems can be
applied to neurological diseases and disorders have been discussed in the review. In
conclusion, optimal delivery systems for NTFs will be needed for reliable and meaningful
clinical benefits; ideally, delivering a time and dose-controlled release of bioactive multi-
NTFs at different individual optimal kinetics to achieve multi-functions in target tissues
is significant preferred.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction systems. Over the past two decades, scientists have had greatNeurotrophic factors are polypeptides primarily known to
regulate the survival and differentiation of nerve cells during




ang Pharmaceutical Univexpectations for NTFs in the treatment of neurological disor-
ders, including the most common central neurodegenerative
diseases, Alzheimer’s (AD) and Parkinson’s (PD) [1]. This
approach may also prove effective for the peripheral nervesity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
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tients and many of whom will be subjected to life-long
disability [2]. Moreover, NTFs also play an important role in
the development of potential neuroprotective glaucoma and
hearing disorders treatments [3e5]. Despite their obvious
attractiveness as therapeutic agents, they have some serious
restrictions in clinical use. The most limiting of these is their
short biological half-life and vulnerability to structural
disruption or modification, leading to loss of bioactivity.
Therefore, protein drug delivery systems are needed not only
to improve the biological utilization by sustained release of
bioactive NTFs to target site at sufficient concentration, but
also to protect their bioactivity from degradation by direct
exposure to harsh environments. There has been a growing
interest to develop new strategies for effective delivery of
NTFs. This article reviews some widely investigated NTFs and
their delivery systems, summarizes the difficulties in their
neurodegenerative diseases therapy and the most pertinent
evaluation system for testing delivery systems, and finally
provides perspectives for advanced nerve repair strategies
that may hold promise for enhancing therapeutic efficacy.2. Neurotrophic factor
Nerve growth factor (NGF), discovered by R. Levi Montalcini
almost 60 years ago, is regarded as the first discovered and as
an important member of neurotrophin family [6]. Later, three
NGF homologous growth factors were identified: the brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3)
and NT-4/5. Each has its distinct and/or overlapping activities
within the developing peripheral and central nervous systems
and are collectively indicated as neurotrophins [7]. Widely
studied NTFs also include the glial cell line-derived neuro-
trophic factor (GDNF, belonging to the transforming growth
factor-b superfamily), the glial growth factor (GGF) (a member
of the neuregulin family), neuropoietic cytokines [such as
ciliary neurotrophic factor (CNTF), leukemia inhibitory factor
(LIF)] and other cytokines [2]. Since important NTFs in adult-
hood as well as development, reducing the level of one or
more of these proteinsmay be responsible for the neurological
disorders. Each of the factors has been employed in the neu-
rorestorative therapy in some form or another in clinical tri-
als. To brief illustrate, neurotrophin family and GDNF are
addressed when selecting or designing a delivery system in
this review.
Although GDNF shows only limited amino-acid sequence
homology with the member of neurotrophins family, it has
somewhat conformational similarity as they all have the
characteristic cystine knot structure motif with the formation
of three disulphide bonds. The above proteins differ in their
spectrum of action when applied as a single factor. NGF is
essential for the development and phenotypicmaintenance of
neurons in the peripheral nervous system (PNS) and for the
functional integrity of cholinergic neurons in the central
nervous system (CNS) [1]. It has been considered as a very
powerful and selective growth factor for sympathetic and
sensory neurons, especially primarily survival and axonal
outgrowth of sensory neurons [8]. Meanwhile BDNF supports
the survival and maintenance of sensory neurons, retinalganglia, certain cholinergic neurons, spinal motor neurons
and somedopaminergic neurons [1]. NT-3 helps to support the
survival and differentiation of existing neurons, and also en-
courages the growth and differentiation of new neurons and
new neurons and synapses [1]. GDNF shows pronounced ef-
fects on the survival of midbrain dopaminergic neurons. Even
more interesting, it is identified to be key factor for motor
axonal regeneration for its ability to promoting axonal elon-
gation [9,10].
Neurotrophin family binds to two different receptors: high
affinity binding via tropomyosin receptor kinase (Trk)-A, B or
C and low affinity nerve growth factor receptor (p75 neuro-
trophin receptor, P75NTR). NGF binds TrkA; BDNF, NT-4/5
binds TrkB; NT-3 binds TrkC. Finally, the binding of GDNF by
its homodimeric receptor tyrosine kinase complex leads to
activation of the TrkA pathway, which in the case of GDNF is
highly complex and interdependent [1].3. Current delivery strategies for
neurotrophic factors
Though applied to a wide spectrum of neurological diseases,
the clinical utilization of NTFs, , remains limitations by
important adverse events induced by exposing non-targeted
tissues [11] coupled with the mild side effects like those
derived from the effects of NGF on pain system [12]. These
effects are especially when systemically administration.
Moreover, NTFs undergo very short biological half-life in cir-
culation and rapid degradation in vivo, and also present poor
permeability across the biological barriers [11]. Therefore, to
an efficacious clinical outcome, localized delivery for NTFs is
preferred. Nevertheless, the clinical outcome remained,
however generally unsatisfactory, and was probably due to
inadequate NTFs doses and/or release kinetics at the optimal
location, undesired initial burst release, and the use of single
NTFs rather than multiple factors as occurs naturally [2].
There have been many attempts to deliver various NTFs to
target sites by using diverse types of synthetic and natural
materials in order to modulate the release kinetics. Generally,
the proteins were designed to be immobilized in the systems
through non-covalent or covalent means.
3.1. Non-covalent neurotrophic factors binding
Non-covalent binding includes physical entrapment, adsorp-
tion or electrostatic interaction. NTFs have been immobilized
in hydrogels, microspheres, electrospun nanofibers and
combined systems, which serve as depots for sustained local
release of protein. These systems generally control drug
release by the mechanisms of slow degradation of the mate-
rials, slow drug diffusion or a combination of both.
3.1.1. Hydrogels
Hydrogels have been used in both clinical and basic research
to aid in tissue and organ regeneration and engineering. They
are water-swollen networks of lightly cross-linked polymer
chains, which allow hydrogels to reversibly dehydrate and re-
swell depending on the environment, thus enabling drug up-
take and release [13]. Hydrogels most often used in
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but also fall under the definition of chemically across-linked
synthetic hydrogels with viscoelastic properties. A wide
range of natural and synthetic hydrogels have been explored
for the fabrication of artificial nerve conduits (NC), which is
the instrument for repairing damaged peripheral nerves, and
some of them have been approved by regulatory authorities
for use in human. However, presentlymarked artificial NC has
limited functional capacity for repairing even small-sized
nerve gaps. Many researches demonstrated that NTFs play
an indispensable role for neuronal survival and axonal
regeneration, which is a prerequisite for effective functional
re-innervation of severed peripheral nerve. Prolonged delivery
of NTFs was also achieved by embedding the drug substances
into NC wall, polymeric coating or filled into the lumen of
artificial NC. These technologies have been summarized in a
recent reviewpaper andwill not be discussed here in detail [2].
One limitation of these technologies is the initial burst of NTFs
release, as excessive initial NTFs doses can hamper the early
axonal regeneration. To minimize the burst release of the
NTFs, other sustained strategies including microspheres and
electrospun nanofibers have been combined with NC and
further developed for localized release of NTFs. This topic will
be discussed in later sections.
In addition, injectable hydrogel offer considerable promise
for controlled and sustained release over time via minimally
invasive administration. A variety of materials have been
tested as potential vehicles for delivery of NTFs in the treat-
ments of neurodegenerative diseases. For example, injections
of an acrylated poly(ethylene glycol) (PEG) plus poly lactic acid
(PLA) hydrogel that released NT-3 over a several week period
were reported to improve behavior and axon growth after
spinal cord injury [14]. In another study, Sofroniew et al.
employed an amphiphilic diblock copolypeptide hydrogels
(DCH), a highly versatile and finely tunable injectable hydro-
gels, to form depots that provide sustained delivery of NGF.
This proved that DCH can provide a temporary gradient of
bioactive protein that is active over a distance of at least
severalmm in forebrain that is sustained over a subacute time
course of at least 4 weeks [15]. Mechanical and physical fea-
tures which are helpful to consider when constructing a
hydrogel include the strength and stiffness, themesh size and
porosity as well as the overall architecture and physical di-
mensions of the hydrogel. Many of these characteristics can
significantly contribute to the effectiveness the hydrogel, from
biocompatibility with tissues to how therapeutic agents are
released from the hydrogel. In general, fewer cross-linksmake
for softer hydrogels that are ideal for brain and other soft
tissues. More specially, the injectable hydrogels with storage
modulus (G’) values somewhat lower than that of brain tissue
are easily injected, and self-assemble into well-formed de-
posits of gel networks after injection, with a specifically
desired range of brain at just below that of CNS tissues are
preferred.
Meanwhile, hydrogels has also been investigated for the
delivery of NTFs as the treatment of sensorineural hearing
loss (SNHL). Havenith et al. applied Gelfoam (a gelatin
sponge) infiltrated with BDNF onto the round window mem-
brane (the key barrier separated the middle ear and inner ear)
of deafened guinea pigs and evaluated the effect of thistreatment by structural and functional measures. In the two
weeks of Gelfoam BDNF treatment, the survival of spiral
ganglion neurons in the inner ear was observed in the low
turn of the cochlea, but no significant improvement was
observed in the apical turn of the cochlea. This was likely due
to such a small amount of drug reaching the apical turn [5].
This issue could be resolved by increasing the residence time
of hydrogels on the round window membrane in order to
achieve more uniform drug distribution in the inner ear. On
the other hand, the cochlear implant (CI) provides electric
hearing to patients with certain types of severe hearing loss
induced by hair cell loss. Until recently, it was recognized that
the process of inserting an electrode deeply into cochlea
would destroy all remaining acoustic hearing due to various
complications associated with implantation. Hence many re-
searchers tried to find an opportunity to combine the use of
drugs with CI to reduce trauma to the inner ear to prevent
further degeneration of hearing after implantation [16]. NTFs
were also delivered from modified CI by either physically
absorbing or entrapment in the coating of CI. Directly ab-
sorption of protein on the CI frequently led to the loss of
bioactivity and a high initial burst release. Instead, the
hydrogel coating of CI provided an alternative to solve this
problem. For example, the combination of the conducting
polymer poly(3.4-ethylenedioxythiophene) (PEDOT) with an
arginineeglycineeaspartic acid (RGD)-modified alginate
hydrogel loaded with BDNF created an effective, non-
cytotoxic, and clinically relevant CI coating. A substantial
release of bioactive BDNF into the cochlear fluids within 1
week of implantation with a BDNF-soaked hydrogel-coated
implant and this bioactive effect was sustained 2 weeks after
implantation. The hydrogel coating of CI was dual-functional:
the coating improved the performance of CI, including
reduced electrode impedance and improved charge delivery;
in addition, the hydrogel also provided the reservoir for
bioactive molecules [17].
3.1.2. Microspheres
An alternative to non-covalent binding is the encapsulation of
protein into microspheres, which are often employed as
controlled release systems delivered by stereotactic injections
to localized disease or injury sites. Many biodegradable syn-
thetic polymers such as poly (lactic-co-glycolic acid) (PLGA)
and natural biomaterials have been used to fabricate this type
of controlled drug delivery systems. Specific properties of
these materials such as the degradation rate can be modified
to tailor for particular applications. It has been assumed that a
loaded protein drug is released gradually following the poly-
mer degradation kinetics [18].
Natural biomaterials such as collagen, gelatin, chitosan
and alginate possess the advantages of excellent protein
compatibility and biocompatibility over the synthetic poly-
mers. Moreover,many of themhave proved to enhance neural
cell adhesion, survival and neurite outgrowth of neurons.
While synthetic polymers offer a great choice and flexibility
for developing microspheres with customized degradation
properties to meet with nerve regeneration rate [2].
An ideal microspheres formulation should have a reason-
ably high protein encapsulation efficiency, loading capacity,
and sustained release of the loaded protein with retained
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efficiencies are most critical simply due to the extremely high
price of therapeutic proteins. Different techniques have been
developed to avoid the protein denaturation during the
microencapsulation process. Since proteins in the solid state
are believed to maintain their bioactivity by drastically
reducing conformational mobility in comparison to the large
structural change found in the dissolved state, several labo-
ratories are working on protein microencapsulation following
S/O/O (solid-in-oil-in-oil) or S/O/W (solid-in-oil-in-water)
method. It is, however, noted that dispersing protein particles
in organic solvent is not easy. Whichever S/O/O or S/O/W
techniques are employed, it is essential to prepare a protein
powder with small particle size in the first S/O suspension
step. Micronization methods include lyophilization, spray
drying, and spray freeze-drying. The complicated micron-
ization step compromises the power of protein protective
ability via S/O/O or S/O/W method. Later, the techniques are
further modified so that the protein can be firstly dissolved in
dimethyl sulfoxide (DMSO) or methanol without inducing the
loss of activity. The S/O emulsion is then dispersed into the
polymer solution to generate microspheres [18]. Similarly,
GDNF was directly suspended in vitamin E (Vit E) and
dispersed in PLGA solution to obtain microspheres under very
mild conditions (microspheres elaboration method described
in Fig. 1). This modified method led to a high microspheres
production yield of 76.3  8.4% but a low protein encapsula-
tion efficiency of 27.8  3.1%. The authors observed a burst
release of 60% of the loaded GDNF within the first day and
then continuous release was reportedwith almost 100% of the
total GDNF recovered at the end of assay (day 133). They also
suggested that the protein was released in its bioactive form
for more than three months as the evidence of the survival of
photoreceptor and retinal ganglion cells in vitro. Furthermore,
the intravitreal injection of GDNF/Vit E PLGA microspheres inFig. 1 e Preparation of protein loadedthe experimental animal model of glaucoma significantly
increased the survival of retinal ganglion cells compared to
GDNF, Vit E or blankmicrospheres. The effect was lasted for at
least eleven weeks. It was suggested that the formulations
preparedmight be clinically useful as a neuroprotective tool in
the treatment of glaucomatous optic neuropathy [19].
Reducing the initial burst release still remains a challenge
when using microspheres. To avoid this issue, some groups
have investigated the novel immobilized strategies of proteins
in microspheres rather than the absorption of protein on
polymer (Fig. 2A). For instance, Yuan and Luo et al. used ion-
ically cross-linked chitosan microspheres fabricated by the
emulsion-ionic cross-linking method with sodium tripoly-
phosphate (STPP) as an ionic cross-linking agent. The NGF
encapsulation efficacy ranged from 63% to 88% depending on
the concentration of STPP. They reported an initial burst
release of 18 to 45% in the first 12 hand the release profiles
were also influenced by the concentration of STPP. The higher
level of STPP, the slower release of NGF as observed. After the
burst stage, the slow release manner was observed over 7
days. However, the total release of encapsulated NGF from the
microspheres did not take place at the end of 7 days, indi-
cating NGF retained in the formulations. The result was
attributed to the electrostatic interactions between positively
NGF (isoelectric points of 9.0e9.35) and negatively charged
STPP. In addition, the released NGF was capable of main-
taining the viability of PC12 cells, as well as promoting their
differentiation [20]. Taken together, electrostatic interaction
methods provided potential strategies to immobilize the pro-
teins in the polymers if appropriately designed (Fig. 2B).
Another interesting approach to improve the immobiliza-
tion of NTFs in the microspheres is to apply the natural
binding properties of proteins to the component of the
extracellular space (ECS) based on their affinity for pro-
teoglycans, such as collagen, or glycosaminoglycans, such asmicrospheres by S/O/W emulsion.
Fig. 2 e Illustration of non-covalent neurotrophic factors
binding strategies in microspheres. (A) Adsorption of
neurotrophic factors through physicochemical interaction
with polymer; (B) Ionic complexation of neurotrophic
factors with oppositely charged polymer and the protein
release occurs by ion exchange mechanism, which is
highly sensitive to the environmental conditions;
(C) Affinity-based release of neurotrophic factors from the
extracellular matrix which are favorably presented to their
receptors.
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the interactions between the drug and matrix in a manner
independent of the properties of the matrix itself. The
frequently employed affinity-based delivery system isFig. 3 e Fabrication technique of neurotrophic factors loaded elec
release; (B) Blend electrospinning led to moderate sustained pro
provide proper sustained protein release due to their long diffuheparin-based delivery system, although these factors do not
show a high affinity. As a result of it, a molar excess of
immobilized heparin binding was required in the systems to
overcome the transient nature of binding interactions and to
facilitate effectively sustained release. Mohtaram et al.
described the affinity-based delivery systems for NTFs
recently [21]. Kraskiewicz et al. created biomimetic hollow
microspheres based on collagen to immobilize NGF by using a
templatemethod. The extremely high loading efficiency of the
reservoir systemwas proven (90e99%), but the burst release of
NGF was observed, as the evidence of about 70 % of total
protein released in the first 2 days [22].
3.1.3. Electrospun fibers
Electrospinning is a popular technique for preparing tissue
engineering scaffolds due to its relative simplicity regarding
the generation of fibrous scaffolds with nano- or submicron-
scale dimensions, which morphologically resembles the nat-
ural ECM. Due to the possibility of ultrathin fiber diameters,
electrospun fibrousmatrices have a large specific surface area
which enables effective delivery of biomolecules. Further-
more, the loose bonding between fibers is beneficial for tissue
growth and cell migration. These characteristics endue elec-
trospinning with superiority in preparation of bioactive scaf-
folds. Currently electrospun fibers could be made from a wide
range of starting materials, including PLGA, poly(vinyl alco-
hol)(PVA) and poly (b-caprolactone) (PCL) for encapsulation of
growth factors [23]. The easiest way to load biomolecules into
electrospun fibers is to dip the scaffolds into an aqueous phase
of proteins. With this approach proteins can attach to the
scaffolds via physical absorption. Although this approach
gives little interference with the activity of loaded bio-
molecules, it is seldom employed due to the uncontrolled
release profiles (Fig. 3A). Another approach to loading proteins
approach is the using blend electrospinning, where proteinstrospun scaffolds. (A) Physical absorption led to fast protein
tein release; (C) Instead, coaxial electrospinning might
sion path.
Fig. 4 e Schematic showing the hydrogel/microspheres
constructs as formed for implantation. Hydrogels were
made that encapsulated standard PLGA (rostral, left) and
carboxylated PLGA (caudal, right) microspheres into each
end. BDNFmicrospheres were encapsulated and implanted
into rostral tissues (targeting striatum) while the GDNF
microspheres were oriented in caudal tissues (targeting
substantia nigra). The GDNF group had hydrogels
containing slow releasing BSA and fast-releasing GDNF.
The BDNF group was implanted with hydrogels carrying
slow-releasing BDNF and fast-releasing BSA.
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electrospinning process to create a hybrid scaffold (Fig. 3B).
Valmikinathan et al. employed the blend electrospinning
technology to incorporate the bovine serum albumin (BSA)-
NGF complex into electrospun fibers and their results showed
that a sustained release of NGF was obtained for at least 28
days with the relatively lower burst initial release (below 10%
of total protein release at the first 1 day) [24]. Coaxial elec-
trospinning, also known as co-electrospinning, is yet another
approach to loading biomolecules within fibers. In this
approach, two solution (typically polymer solution and bio-
logical solution) are coaxially and simultaneously electrospun
through different feeding capillary channels in one needle to
generate composite fibers with core-shell structures (Fig. 3C).
Liu et al. developed a novel composite NC comprised of pol-
y(lactic acid-caprolactone) andNGF by coaxial electrospinning
of polymer for the shell and BSA/NGF for the core. Although no
in vitro release data of NGF showed, it was concluded that the
performance of composited NC was not statistically different
from the positive autograft control after sciatic nerve injury,
which has provided the clinical “gold standard” for a long
period of time in peripheral nerve repair research [25].
3.1.4. Combined systems
Although hydrogels, microspheres and electrospun fibers are
widely used in controlled release systems for the treatment of
neurological disorders, obtaining extended, uniform drug
release with little initial burst has been challenging [21]. On
the other hand, functional recovery from neurological dis-
eases and disorders can only be achieved through the delivery
of multiple therapeutic agents, each which requires different
time courses of release. For example, GDNF should be released
quickly to improve survival during the acute inflammatory
response which typically kills the graft within weeks of im-
plantation. Alternatively, BDNF could be released over a
period of months to elicit axon extension and tissue devel-
opment [26]. The different approaches described in this sec-
tion (hydrogels, microspheres or electrospun fibers) can be
combined to obtain above effects.
In one example, Han et al. proposed a combined delivery
system strategy for sustained release of NGF by the composite
comprised of PCL electrospun fiber coupledwith poly(ethylene
glycol)-poly(b-caprolactone) diacrylate (PEGPCL) hydrogel. The
combined delivery system exhibited stable, near-linear, sus-
tained release of the model protein BSA for over two months
with a significant reduction in initial burst release, as well as
NGF over 28 days in vitro. Bioactivity of NGF was also assessed
by examining PC12 cell neurite extension and the results
showed the releasedNGF remained bioactive over 14 days [27].
In another example, PLGA microspheres were encapsulated
withindegradable poly (ethylene glycol) (PEG)-basedhydrogels
in a spatial orientation to deliver BDNF or GDNF to brain areas
associated with Parkinson’s disease (striatum and substantia
nigra, respectively). The ability to control the spatial and
temporal release of a therapeutic agent was studied using two
preparations of neurotrophic-loaded microspheres incorpo-
rated into hydrogel strands designed to release GDNF more
quickly and BDNFmore slowly (Fig. 4). This would allow GDNF
to have a positive impact on transplant survival and BDNF to
elicit axon extension over a period of months [26].3.2. Covalent neurotrophic factors binding
Covalent immobilization is another strategy for retaining
growth factors for longer periods of time at the target site. Co-
valent immobilization of growth factors was not a previously
expected to maintain biological activity because it may nega-
tively affect their binding to the receptors and the subsequent
dimerization of the receptors in the plane of the membrane.
Nevertheless, if appropriately designed, conjugated growth
factors, also called tether growth factors, offer important con-
trol over the amount and distribution of these component in
solidmatrices and facilitate the establishment of growth factor
gradients. Chen et al. covalently cross-linked NGF with the
glutaraldehyde composite of gelatin-tricalcium phosphate
membranes via carbodiimide. After immobilized, NGF can be
released from the membrane at least for 60 days and the mol-
ecules released fromthemembrane still remains the bioactivity
which promotes the neurite outgrowth of PC12 cell [28].4. Challenges and outlook
Over the past two decades, numerous clinical trials involving
several different NTFs and neurodegenerative diseases have
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claimed successes do not yet allow one to declare victory [11].
It is because NTFs pose a number of unique and difficult de-
livery issues. The challenges still exist for further develop-
ment of NTFs delivery systems includes concerns about (1)
protein instability, (2) difficulties in release kinetics control,
and (3) unclear therapeutic window.
4.1. Protein instability
Maintaining protein bioactivity within delivery systems will
be essential for further clinical application of NTFs, because
the loss of bioactivity of a protein might not only be detri-
mental to the therapeutic potential, but could also cause
immunogenic effects related to exposure of non-native pep-
tide epitopes [29]. Despite the few success stories using
various polymers in sustained delivery of NTFs in preclinical
research, it needs to be mentioned that the instability of
protein during preparation, storage and degradation period is
a general problem for polymeric protein delivery system.
During the complex preparation process, the growth factor
activity might reduce; even through hydrogels delivery sys-
tems greatly benefit from their simplicity, conformational
changes and denaturation are widespread issues leading to
lose of protein activity as well as the irreversible binding of
growth factors with polymers, such as PLGA which is attrac-
tive for biomolecule delivery because of its tailored degrada-
tion rate to achieve controlled release. Although using
hydrophilic additives (e.g. PEG composite) was reported to
minimize the interaction between protein and polymers, the
harmful effect still exist [30]; Protein adsorption and dena-
turation at the water/solvent interface is one of the major
factors for decreased protein bioactivity occurring during the
microencapsulation process [18]; In fact, it is well recognized
that high voltage and contact with organic solvents during the
electrospinning process may be harmful to the growth factor
activity [23]. Therefore, optimizing protein stability during the
preparation process is a major challenge for effective protein
delivery from sustained systems.
Currently, there are a few of effective approached to pro-
tect growth factors within their delivery systems. One is using
the human serum albumin (HSA) or BSA, which occupies the
interfaces and shields the therapeutic proteins from contact
with hydrophobic surfaces. In addition, they act as proton
scavengers during the synthetic polymer degradation process
where the acidic microenvironment induced by hydrolysis
products of polyesters is also likely to be destructive to growth
factor integrity. Some authors used HSA or BSA as protein
stabilizer, but they rarelymentioned the effect of applied ratio
of the additive to protein (10e50 folds in mass ratio was
frequently employed in their work) on growth factor stability
[20,27,31]. Meanwhile, a BSA concentration of 0.1% is generally
incorporated in most protein release studies in order to keep
proteins from aggregation, misfolding and absorption [32,33].
However, 1% BSA in release medium was reported showing a
benefit in the recovery of GDNF as compared with 0.1% BSA
[19]. Besides, 0.02e0.05% Tween 20 or Tween 40 was
frequently used as an additive in the release medium to offer
protein protection [22,34,35]. Another approach is adding pH
regulators within the delivery systems to maintain pH duringpolymers degradation. The hydrophilic polymer PEG was
employed to maintain pH within the delivery systems which
functioned as porogen to allow acidic degraded products to
rapidly release to outer environment [36], while poorly water-
soluble basic salts such as Mg (OH)2 was used to neutralize
acidic microenvironment [37]. Moreover, if lyophilization is
subjected to be used during the formulation preparation pro-
cess, lyoprotectants like sucrose and dextran within formu-
lations might avoid the protein from degradation [23].
4.2. Difficulties in release kinetics control
The biological effects of NTFs depend on the precise delivery
paradigm. Inadequate NTFs dose and release kinetics often
led to aberrant axonal growth, which cannot be improved by
further NTFs delivery [2]. Instead, the initial burst release of
NTFs results in inhabitation of the early axonal regeneration.
Optimal NTFs release kinetics must be compatible with
axonal growth and regeneration, which means that NTFs
released must be in keeping with physiological nerve and
reinnervated organ regeneration [2]. However, the exact ki-
netics required for therapeutic benefit is currently not clear
and likely varies between situations [11]. A further complica-
tion for treating neurodegenerative diseases is that adequate
levels of NTFsmust bemaintained for very long period of time
(i.e., for years). Unfortunately, traditional pharmaceutical
formulations and delivery approaches are unable to solve this
problem. Nevertheless, the sustained delivery of NTFs also
provides a potential for subsidiary nerve protection over short
period (i.e., for months), which is regarded as key step before
further medical treatments. A very effective means to
improve functional axonal regeneration is by controlled de-
livery ofmultiple NTFswith their individually optimal kinetics
[2,26]. To couple with the optimal kinetics for two or more
proteins, suitable delivery systems must be developed to
enable more efficient release kinetics.
To overcome the long-standing delivery issues, gene
transfer has emerged as a practical means of potentially
providing the ‘enabling’ technology required for translating
the use of these proteins into viable biotherapeutics for
neurodegenerative diseases [11]. In addition, it is widely
accepted that Schwann cells play an indispensable role in
axonal regeneration. Therefore, efficient use of such glial cells
at appropriate sites may improve regenerative efficacy,
despite the fact that the isolation and culturing of persynaptic
Schwann cells on large scalemay present new challenges [38].
As a result of this, stem cells, like adipose-derived stem cells,
have been proposed as alternative to obtain Schwann cells
[39,40]. Although gene transfer and cells transplantation have
shown mediate beneficial effects on nerve regeneration,
clinically relevant protocols on safe and efficient use of them
are yet to be developed.
4.3. Unclear therapeutic window
The effect of NTFs are dose-dependent [11]. Currently, there is
no available data concerning the therapeutic concentration of
NTFs in targeted tissues or organs that can be used to evaluate
the efficient therapeutic effect. To define the therapeutic
window of NTFs, pertinent evaluation approaches should be
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ably be practiced in scale and then the complicated biological
effect would be assayed widely. Because of this, in vitro
bioassay of NTFs is preferred, including the employment of
PC12 cells and chicken embryonic dorsal root ganglia (DRG)
methods. PC12 cells have been widely used as cell models for
neuronal differentiation in response to exogenous signals,
such as NTFs and neurotransmitters [41]. Previous reports
demonstrated that effective NGF to stimulate PC12 cell neurite
outgrowth is in the range of 0.1e50 ng/ml [42]. Another in-
vestigators applied DRG bioassay to optimize axonal growth
response of NTFs and the results showed that the ideally dose
was observed at 1e10 ng/ml of GDNF or NGF when used as
single factors, whereas the optimal dose range was 0.1e1 ng/
ml for combined GDNF and NGF [9]. However, in vitro data
should be ‘translated’ to in vivo information before clinical
application, which met with enormous challenge. Some
complications in a human clinical setting include genetic
background, lifestyle, physical activity and age of the patients
as well as variable pathology and additional medications,
which all may affect the required dose. In conclusion, suc-
cessful NTFs delivery requires dosage customization for each
factor and delivery system, in both preclinical model and
clinical case.5. Conclusion and summary
The reliable and meaningful clinical benefits of NTFs will
intimatelydependon their optimal localizeddelivery ina given
context. A delivery system designed for nerve regeneration
should (ⅰ) provide a time and dose-controlled release of the
bioactive NTFs and (ⅱ) offer multiple NTFs delivery with indi-
vidually optimal kinetics to achieve multi-functions (e.g. pre-
vention of neuronal death and promotion of axonal growth).
Additional requirements for a carrier include high biocom-
patibility, adequate biodegradability, ease of manufacturing
(reproducibility and scale up), and cost effectiveness. Partic-
ular challenge for developing an optimal delivery systems for
NTFs encompass the achievement ofmaintain optimal protein
retention over a long period of time in target tissues. Opti-
mizing and customizing sustained delivery systems of NTFs
require continued attention but will hopefully lead to more
efficient therapies for neurological disorders.
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